Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report)'s stock had its "overweight" rating restated by equities researchers at Cantor Fitzgerald in a report released on Tuesday, Benzinga reports. They currently have a $116.00 price target on the biopharmaceutical company's stock. Cantor Fitzgerald's target price would indicate a potential upside of 111.49% from the company's current price.
Several other analysts also recently commented on the company. The Goldman Sachs Group increased their price objective on Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the stock a "buy" rating in a research note on Friday, August 2nd. TD Cowen increased their price objective on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a "buy" rating in a research note on Monday. Wedbush increased their price objective on Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the stock a "neutral" rating in a research note on Friday, August 2nd. Royal Bank of Canada reissued an "outperform" rating and issued a $77.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Thursday, September 26th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and set a $111.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, July 23rd. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical has a consensus rating of "Moderate Buy" and a consensus target price of $88.29.
Read Our Latest Analysis on Ultragenyx Pharmaceutical
NASDAQ:RARE traded up $0.39 on Tuesday, hitting $54.85. The stock had a trading volume of 92,439 shares, compared to its average volume of 769,195. The business's fifty day moving average is $55.85 and its 200 day moving average is $47.63. The company has a market cap of $5.06 billion, a PE ratio of -7.51 and a beta of 0.57. Ultragenyx Pharmaceutical has a 52 week low of $31.52 and a 52 week high of $60.37.
Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.52) EPS for the quarter, topping the consensus estimate of ($1.64) by $0.12. The firm had revenue of $147.03 million during the quarter, compared to the consensus estimate of $123.20 million. Ultragenyx Pharmaceutical had a negative return on equity of 266.02% and a negative net margin of 121.57%. The company's quarterly revenue was up 35.7% compared to the same quarter last year. During the same period in the prior year, the business posted ($2.25) earnings per share. Equities analysts predict that Ultragenyx Pharmaceutical will post -6.28 earnings per share for the current fiscal year.
In other news, CFO Howard Horn sold 7,465 shares of the firm's stock in a transaction on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total value of $393,853.40. Following the completion of the transaction, the chief financial officer now directly owns 92,301 shares of the company's stock, valued at $4,869,800.76. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO Howard Horn sold 7,465 shares of the firm's stock in a transaction on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total value of $393,853.40. Following the completion of the transaction, the chief financial officer now directly owns 92,301 shares of the company's stock, valued at $4,869,800.76. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Emil D. Kakkis sold 20,000 shares of the firm's stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $55.85, for a total value of $1,117,000.00. Following the completion of the transaction, the chief executive officer now directly owns 2,223,985 shares of the company's stock, valued at $124,209,562.25. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 47,556 shares of company stock valued at $2,519,367 over the last ninety days. 5.80% of the stock is currently owned by insiders.
Several large investors have recently added to or reduced their stakes in RARE. Headlands Technologies LLC bought a new stake in Ultragenyx Pharmaceutical during the first quarter valued at $28,000. nVerses Capital LLC bought a new stake in Ultragenyx Pharmaceutical during the second quarter valued at $33,000. UMB Bank n.a. boosted its stake in Ultragenyx Pharmaceutical by 58.1% during the second quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company's stock valued at $39,000 after buying an additional 352 shares during the period. GAMMA Investing LLC boosted its stake in Ultragenyx Pharmaceutical by 622.3% during the first quarter. GAMMA Investing LLC now owns 1,004 shares of the biopharmaceutical company's stock valued at $47,000 after buying an additional 865 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its stake in Ultragenyx Pharmaceutical by 67.7% during the first quarter. Allspring Global Investments Holdings LLC now owns 3,318 shares of the biopharmaceutical company's stock valued at $155,000 after buying an additional 1,339 shares during the period. Institutional investors own 97.67% of the company's stock.
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ultragenyx Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultragenyx Pharmaceutical wasn't on the list.
While Ultragenyx Pharmaceutical currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.